CIK 0001737287
- Non-accelerated filer
- Smaller reporting company
Allogene Therapeutics, Inc.
Sign in to watch- Ticker
- ALLO
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 823562771
- Phone
- +1 650-457-2700
- Business address
- 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
- 4 Derivatives Options or other derivatives
- 4 Grant or award Director acquired 16,377 shares (grant or award)
- 4 Grant or award Director acquired 16,377 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 4 Open-market sale Chief Technical Officer sold 48,828 shares at an average $26.76 ($1,306,774)
- 4 Other disposition Director disposed of 598,935 shares (other)
- 4 Other acquisition President and CEO acquired 11,753 shares (other)
- 4 Open-market sale 10% owner sold 1,918,755 shares at $29.38 ($56,373,022)
- 4 Other acquisition President and CEO acquired 11,753 shares (other)
- 4 Other disposition Director disposed of 598,937 shares (other)
- 4 Grant or award Chief Technical Officer acquired 37,050 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 49,400 shares (grant or award)
- 4 Grant or award Director acquired 115,333 shares (grant or award)
- 4 Grant or award President and CEO acquired 173,000 shares (grant or award)
- 4/A Open-market buy Director bought 194,445 shares at $18.00 ($3,500,010)
- 4 Other acquisition Director acquired 6,535 shares (other)
- 4 Open-market buy Director bought 15,000 shares at $18.00 ($270,000)
- 4 Open-market buy Director bought 30,000 shares at $18.00 ($540,000)
- 4 Conversion Director acquired 18,716 shares (conversion)
- 4 Open-market buy President and CEO bought 40,000 shares at $18.00 ($720,000)
Page 13 of 14 · 275 filings